MONTE ROSA THERAPEUTICS INC (GLUE)

US61225M1027 - Common Stock

7.14  +0.09 (+1.28%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GLUE. GLUE was compared to 565 industry peers in the Biotechnology industry. While GLUE has a great health rating, there are worries on its profitability. GLUE has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

GLUE had negative earnings in the past year.
GLUE had a negative operating cash flow in the past year.
In the past 5 years GLUE always reported negative net income.
In the past 5 years GLUE always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of GLUE (-37.89%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -58.11%, GLUE is in the better half of the industry, outperforming 62.28% of the companies in the same industry.
Industry RankSector Rank
ROA -37.89%
ROE -58.11%
ROIC N/A
ROA(3y)-32.15%
ROA(5y)-47.76%
ROE(3y)-45.59%
ROE(5y)-87.89%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

GLUE has more shares outstanding than it did 1 year ago.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -0.14, we must say that GLUE is in the distress zone and has some risk of bankruptcy.
GLUE has a better Altman-Z score (-0.14) than 62.99% of its industry peers.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.14
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 6.03 indicates that GLUE has no problem at all paying its short term obligations.
GLUE's Current ratio of 6.03 is fine compared to the rest of the industry. GLUE outperforms 60.85% of its industry peers.
GLUE has a Quick Ratio of 6.03. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GLUE (6.03) is better than 61.39% of its industry peers.
Industry RankSector Rank
Current Ratio 6.03
Quick Ratio 6.03

More info and screens

3

3. Growth

3.1 Past

GLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.97%, which is quite impressive.
EPS 1Y (TTM)31.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.12% on average over the next years. This is quite good.
The Revenue is expected to grow by 78.10% on average over the next years. This is a very strong growth
EPS Next Y41.55%
EPS Next 2Y19.22%
EPS Next 3Y11.07%
EPS Next 5Y18.12%
Revenue Next Year69.35%
Revenue Next 2Y0.33%
Revenue Next 3Y27.23%
Revenue Next 5Y78.1%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.22%
EPS Next 3Y11.07%

More info and screens

0

5. Dividend

5.1 Amount

GLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (12/26/2024, 12:22:35 PM)

7.14

+0.09 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners86.75%
Inst Owner Change8.53%
Ins Owners0.7%
Ins Owner Change-22.25%
Market Cap438.68M
Analysts85.71
Price Target16.76 (134.73%)
Short Float %18.12%
Short Ratio3.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.74%
Min EPS beat(2)21.93%
Max EPS beat(2)41.55%
EPS beat(4)3
Avg EPS beat(4)0.72%
Min EPS beat(4)-69.89%
Max EPS beat(4)41.55%
EPS beat(8)7
Avg EPS beat(8)1.97%
EPS beat(12)9
Avg EPS beat(12)-5.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)242.99%
Min Revenue beat(2)241.21%
Max Revenue beat(2)244.78%
Revenue beat(4)2
Avg Revenue beat(4)90.12%
Min Revenue beat(4)-100%
Max Revenue beat(4)244.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.76%
PT rev (3m)3.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)95.63%
EPS NY rev (1m)14.75%
EPS NY rev (3m)20.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)376.83%
Revenue NY rev (1m)68.12%
Revenue NY rev (3m)137.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.29
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.14
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.24
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.89%
ROE -58.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.15%
ROA(5y)-47.76%
ROE(3y)-45.59%
ROE(5y)-87.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.55%
Cap/Sales 36.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.03
Quick Ratio 6.03
Altman-Z -0.14
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)369.03%
Cap/Depr(5y)744.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.57%
EPS Next Y41.55%
EPS Next 2Y19.22%
EPS Next 3Y11.07%
EPS Next 5Y18.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year69.35%
Revenue Next 2Y0.33%
Revenue Next 3Y27.23%
Revenue Next 5Y78.1%
EBIT growth 1Y8.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.32%
EBIT Next 3Y4.39%
EBIT Next 5YN/A
FCF growth 1Y31.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.71%
OCF growth 3YN/A
OCF growth 5YN/A